• Bert Gordijn
Reference work entry


This chapter is an introduction to the section on neuroenhancement, which is regarded as an intervention in the central nervous system in order to “improve” certain aspects of a person’s “healthy” or “normal” performance. This can be accomplished by pharmaceutical means, surgery, and/or technology. The section on neuroenhancement begins with a chapter looking at pharmaceutical mood enhancement. It then centers on smart drugs followed by a chapter on the use of brain-computer interfaces for enhancement purposes and another one analyzing moral neuroenhancement. The section concludes with a chapter presenting some general reflections on neuroenhancement.


Ethical Debate Academic Debate Moral Enhancement Societal Effect Laser Hair Removal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bacon, F. (1974 [1627]). The new Atlantis. In A. Johnston (Ed.), The advancement of learning and new Atlantis (pp. 1–212). Oxford: Clarendon.Google Scholar
  2. Boot, B. P., Partridge, B., & Hall, W. (2012). Letter to the editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase, 18(3), 181–184.CrossRefGoogle Scholar
  3. de Condorcet, N. (1988 [1795]). Esquisse d’un tableau historique des progrès de l’esprit humain. In A. Pons (Ed.), Esquisse d’un tableau historique des progrès de l’esprit humain suivi de Fragment sur l’Atlantide (pp. 79–296). Paris: Flammarion.Google Scholar
  4. Descartes, R. (1897–1913[1637]). Discours de la méthode pour bien conduire sa raison et chercher la vérité dans les sciences. In C. Adam & P. Tannery (Eds.), Oevres de Descartes (13 vols.). Paris: Léopold Cerf, Band 6.Google Scholar
  5. Eickenhorst, P., Vitzthum, K., Klapp, B. F., Groneberg, D., & Mache, S. (2012). Neuroenhancement among German University students: Motives, expectations, and relationship with psychoactive lifestyle drugs. Journal of Psychoactive Drugs, 44(5), 418–427.CrossRefGoogle Scholar
  6. Gordijn, B. (2006). Medical utopias. Ethical reflections about emerging medical technologies. Leuven/Paris/Dudley: Peeters.Google Scholar
  7. Kramer, P. D. (1993). Listening to prozac: A psychiatrist explores antidepressant drugs and the remaking of the self. New York: Viking.Google Scholar
  8. Normann, C., & Berger, M. (2008). Neuroenhancement: Status quo and perspectives. European Archives of Psychiatry and Clinical Neuroscience, 258, 110–114.CrossRefGoogle Scholar
  9. Partridge, B. J., Bell, S. K., Lucke, J. C., Yeates, S., & Hall, W. D. (2011). Smart drugs “as common as coffee”: Media hype about neuroenhancement. PloS One, 6(11), e28416.CrossRefGoogle Scholar
  10. Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187.CrossRefGoogle Scholar
  11. Wiesing, U. (2008). The history of medical enhancement: From restitutio ad integrum to transformatio ad optimum? In B. Gordijn & R. Chadwick (Eds.), Medical Enhancement and Posthumanity (pp. 9–24). New York: Springer.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Institute of EthicsDublin City UniversityDublinIreland

Personalised recommendations